These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 1816071)

  • 1. Protective humoral immune responses to the human immunodeficiency virus induced in immunized pigs: a possible source of therapeutic immunoglobulin preparations.
    Osther K; Kellermann G; Ugen KE; Williams WV; Weiner DB
    Hybridoma; 1991 Dec; 10(6):673-83. PubMed ID: 1816071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
    Shibata R; Igarashi T; Haigwood N; Buckler-White A; Ogert R; Ross W; Willey R; Cho MW; Martin MA
    Nat Med; 1999 Feb; 5(2):204-10. PubMed ID: 9930869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
    Boudet F; Theze J; Zouali M
    Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1.
    Major JG; Liou RS; Sun LK; Yu LM; Starnes SM; Fung MS; Chang TW; Chang NT
    Hum Antibodies Hybridomas; 1994; 5(1-2):9-17. PubMed ID: 7858187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors.
    Chin LT; Hinkula J; Levi M; Ohlin M; Wahren B; Borrebaeck CA
    Immunology; 1994 Mar; 81(3):428-34. PubMed ID: 7515847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120.
    Wang HW; Cole D; Jiang WZ; Jin HT; Fu N; Chen ZL; Jin NY
    Clin Exp Immunol; 2005 Jul; 141(1):72-80. PubMed ID: 15958072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
    Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
    Gauduin MC; Parren PW; Weir R; Barbas CF; Burton DR; Koup RA
    Nat Med; 1997 Dec; 3(12):1389-93. PubMed ID: 9396610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells.
    Klinman DM; Higgins KW; Conover J
    J Exp Med; 1991 Apr; 173(4):881-7. PubMed ID: 2007856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.